Increasing incidence of parosmia and phantosmia in patients recovering from COVID-19 smell loss

Kathrin Ohla, Maria G. Veldhuizen, Tomer Green, Mackenzie E. Hannum, Alyssa J. Bakke, Shima T. Moein, Arnaud Tognetti, Elbrich M. Postma, Robert Pellegrino, Liang‐Dar Hwang, Javier Albayay, Sachiko Koyama, Alissa A. Nolden, Thierry Thomas‐Danguin, Carla Mucignat‐Caretta, Nick Simon Menger, Ilja Croijmans, Lina Öztürk, Hüseyin Yanık, Denis Pierron, Veronica Pereda‐Loth, Alexia Nunez-Parra, Aldair M. Martinez Pineda, David Gillespie, Michael C. Farruggia, Cinzia Cecchetto, Marco Aurélio Fornazieri, Carl Philpott, Vera V. Voznessenskaya, Keiland W Cooper, Paloma Rohlfs Domínguez, Orietta Calcinoni, Jasper H. B. de Groot, Sanne Boesveldt, Surabhi Bhutani, Elisabeth M. Weir, Cara Exten, Paule V. Joseph, Valentina Parma, John E. Hayes, Masha Y. NivmedRxiv 2021 · DOI

Abstract

Sudden smell loss is a hallmark symptom of COVID-19, with an estimated prevalence between 40% and 75%. This longitudinal study characterizes smell function and recovery up to 11 months post-infection. While quantitative smell ability improves for many, the prevalence of qualitative distortions—parosmia and phantosmia—increases significantly over time. Persistent olfactory dysfunction is also associated with a higher burden of systemic symptoms, suggesting it is a key component of the "long-COVID" syndrome.

Introduction

Smell impairment significantly impacts physical health, mental well-being, and dietary behavior. Early in the pandemic, anosmia (total loss of smell) was identified as a specific early symptom of COVID-19. However, the long-term trajectory of recovery, particularly the emergence of qualitative dysfunctions like parosmia (distorted smells) and phantosmia (phantom smells), remained poorly understood. This study, conducted by the Global Consortium for Chemosensory Research (GCCR), aimed to track these changes over a median of 200 days to better understand the sensory consequences of the virus.

Methods

The study utilized a longitudinal, observational survey design. Researchers used the GCCR core survey, translated into five languages, to track participants at the onset of their illness (S1) and again at a follow-up (S2) ranging from 2 to 10 months later. Smell and taste function were rated on a 0–100 Visual Analog Scale (VAS), and qualitative disorders were self-reported. The final longitudinal dataset consisted of 1,468 participants who had a confirmed COVID-19 diagnosis and initial chemosensory loss.

Results

Quantitative recovery was incomplete for many participants; at follow-up (~200 days on average), approximately 60% of women and 48% of men reported less than 80% of their pre-illness smell ability. A "recovery paradox" was observed: as quantitative detection improved, qualitative distortions skyrocketed. Parosmia prevalence rose from 10.2% at the initial stage to 46.8% at follow-up, while phantosmia rose from 10.1% to 24.7%.

Prevalence of parosmia at initial COVID-19 stage versus follow-up (~200 days) for patients who have and have not recovered from smell loss.

Furthermore, the data suggests that persistent smell loss is a marker for broader systemic issues. "Smell long-haulers" (those regaining <80% of their pre-illness ability) reported significantly more non-chemosensory symptoms, such as fatigue and headache, at follow-up compared to those who recovered more fully (p < .0001).

Discussion

The findings suggest that the olfactory system's attempt to regenerate post-infection often leads to "faulty wiring," manifesting as parosmia. This dysfunction is not an isolated sensory glitch but a potential clinical indicator for the broader long-COVID syndrome. The high prevalence of these symptoms months after infection—affecting nearly half of the cohort—necessitates increased clinical attention and research into treatment options like olfactory training.

Conclusion

While the "volume" of smell may return for many individuals, the "quality" of that sense often degrades over time. Healthcare providers worldwide must be prepared to manage the long-term physical and mental health impacts of persistent parosmia and phantosmia, as conservative estimates suggest millions may be affected globally.

Summary updated

Abstract

Abstract Importance Sudden smell loss is a specific early symptom of COVID-19, with an estimated prevalence of ~40% to 75%. Smell impairment affects physical and mental health, and dietary behavior. Thus, it is critical to understand the rate and time course of smell recovery. Objective To characterize smell function and recovery up to 11 months post COVID-19 infection. Settings, Participants This longitudinal survey of individuals suffering COVID-19-related smell loss assessed disease symptoms and gustatory and olfactory function. Participants (n=12,313) who completed an initial respiratory symptoms, chemosensory function and COVID-19 diagnosis survey (S1) between April and September 2020 and completed a follow-up survey (S2) between September 2020 and February 2021; 27.5% participants responded (n=3,386), with 1,468 being diagnosed with COVID-19 and suffering co-occurring smell and taste loss at the beginning of their illness. Main Outcomes &amp; Measures Primary outcomes are ratings of smell and taste function on a visual analog scale, and self-report of parosmia (smell distortions) and phantosmia (unexplained smells). Secondary outcomes include a checklist of other COVID-19 symptoms. Results On follow-up (median time since COVID-19 onset ~200 days), ~60% of women and ~48% of men reported less than 80% of their pre-illness smell ability. Taste typically recovered faster than smell, and taste loss rarely persisted if smell recovered. Prevalence of parosmia and phantosmia was ~10% of participants in S1 and increased substantially in S2: ~47% for parosmia and ~25% for phantosmia. Persistent smell impairment was associated with more symptoms overall, suggesting it may be a key marker of long-COVID. During COVID-19 illness, the ability to smell was slightly lower among those who did not recover their pre-illness ability to smell at S2. Conclusions and Relevance While smell loss improves for many individuals who lost it due to COVID-19, the prevalence of parosmia and phantosmia increases substantially over time. Olfactory dysfunction is also associated with wider COVID-19 symptoms and may persist for many months after COVID-19 onset. Taste loss in the absence of smell loss is rare. Persistent qualitative smell symptoms are emerging as common long term sequelae; more research into treatment options is strongly warranted given that conservative estimates suggest millions of individuals may experience parosmia following COVID-19. Healthcare providers worldwide need to be prepared to treat post COVID-19 secondary effects on physical and mental health. Trial registration This project was pre-registered at OSF: https://osf.io/3e6zc . Graphical abstract Key Points Question What are the characteristics of smell and taste recovery of COVID-19 patients? Findings In this preregistered observational study of 1,468 participants, smell loss is associated with a higher number of COVID-19 symptoms, and may persist for at least 11 months following disease onset. While a majority of participants report quantitative improvement in their ability to smell, the prevalence of parosmia and phantosmia increases substantially at follow-up. Taste recovers faster than smell, suggesting taste and smell recover separately and can be distinguished by the respondents. Meaning Olfactory dysfunction appears to be a component of long-COVID, with parosmia as a prominent symptom in almost half of those with smell loss. More research into treatment is needed, especially given that olfactory dysfunction is associated with depression and loss of appetite. Health professionals should be aware of these common and long lasting effects.
BibTeX
@misc{ohla2021increasing,
  author = {Kathrin Ohla and Maria G. Veldhuizen and Tomer Green and Mackenzie E. Hannum and Alyssa J. Bakke and Shima T. Moein and Arnaud Tognetti and Elbrich M. Postma and Robert Pellegrino and Liang‐Dar Hwang and Javier Albayay and Sachiko Koyama and Alissa A. Nolden and Thierry Thomas‐Danguin and Carla Mucignat‐Caretta and Nick Simon Menger and Ilja Croijmans and Lina Öztürk and Hüseyin Yanık and Denis Pierron and Veronica Pereda‐Loth and Alexia Nunez-Parra and Aldair M. Martinez Pineda and David Gillespie and Michael C. Farruggia and Cinzia Cecchetto and Marco Aurélio Fornazieri and Carl Philpott and Vera V. Voznessenskaya and Keiland W Cooper and Paloma Rohlfs Domínguez and Orietta Calcinoni and Jasper H. B. de Groot and Sanne Boesveldt and Surabhi Bhutani and Elisabeth M. Weir and Cara Exten and Paule V. Joseph and Valentina Parma and John E. Hayes and Masha Y. Niv},
  title = {{Increasing incidence of parosmia and phantosmia in patients recovering from COVID-19 smell loss}},
  year = {2021},
  doi = {10.1101/2021.08.28.21262763},
  howpublished = {medRxiv},
}
Figure